MRM2

Across TCGA pan-cancer cohorts, MRM2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of MRM2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where MRM2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types MRM2 is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.

CCRCC, HNSC, and LSCC are the cancer types where MRM2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MRM2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	−0.526	<.001	10	view →
HNSC	All	All	+0.205	.008	6	view →
LSCC	Male	II,III,IV	+0.291	<.001	4	view →
LUAD	All	II,III,IV	+0.267	.001	4	view →
PDAC	Female	All	+0.510	.020	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

MRM2–CCRCC

Open the CCRCC breakdown →